FOLH1 and prostate carcinoma: Recently, prostate-specific membrane antigen (PSMA)-Positron emission tomography–computed tomography (PET/CT) based on the ligand 68Ga-PSMA11 has shown the potential to improve the detection of metastatic spread of prostate cancer in patients with biochemical recurrence [3, 4].